Capstone Therapeutics (NASDAQ: CAPS) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $10.5 million.

For earnings history and earnings-related data on Capstone Therapeutics (CAPS) click here.